Vertex Pharmaceuticals Incorporated

Drug Name	Phase	Indication	Designations	Patent
Suzetrigine	Phase 3	Pain	-	Patent 2040
VX-445/TEZ/IVA	Phase 3	Cystic Fibrosis	-	-
VX-121/TEZ/D-IVA	Phase 3	Cystic Fibrosis	-	-
Povetacicept	Phase 3	Primary Membranous Nephropathy	-	-
IVA	Phase 3	Cystic Fibrosis	-
VX-880	Phase 3	Type 1 Diabetes	OrphanFast TrackBreakthrough	-
Lumacaftor	Phase 3	Cystic Fibrosis	-
CTX001	Phase 3	Beta-Thalassemia	-	-
VX-661/Ivacaftor	Phase 3	Cystic Fibrosis	-	Patent 2033
HB/APAP	Phase 3	Acute Pain	-	-
Pegylated Interferon Alfa 2a	Phase 3	Chronic Hepatitis C	-	-
SUZ	Phase 3	Acute Pain	-	-
VX-659/TEZ/IVA	Phase 3	Cystic Fibrosis	-	-
Tezacaftor/Ivacaftor	Phase 3	Cystic Fibrosis	-
ribavirin	Phase 3	Hepatitis C	-
LUM/IVA	Phase 3	Cystic Fibrosis	-	-
Ivacaftor	Phase 3	Cystic Fibrosis	-	Patent 2033
TEZ	Phase 3	Cystic Fibrosis	-	-
TEZ/IVA	Phase 3	Cystic Fibrosis	-	-
Biological/Vaccine	Phase 3	Type 1 Diabetes	-	-
Casgevy Exagamglogene Autotemcel	Phase 3	Sickle Cell Disease	OrphanFast TrackBreakthrough	-
VX-770	Phase 3	Cystic Fibrosis	-	-
Suzetrigine (SUZ)	Phase 3	Acute Pain	-	-
Pregabalin	Phase 3	Diabetic Peripheral Neuropathic Pain	-	Patent 2027
LUM	Phase 3	Cystic Fibrosis	-	-
VX-509	Phase 3	Rheumatoid Arthritis	-	-
VX-809	Phase 3	Cystic Fibrosis	-	-
Telaprevir	Phase 3	Hepatitis C	-	Patent 2028
ELX/TEZ/IVA	Phase 3	Cystic Fibrosis	-	-
VX-147	Phase 3	Proteinuric Kidney Disease	-	-
VX-661 plus ivacaftor combination	Phase 3	Cystic Fibrosis	-	-
Lumacaftor Plus Ivacaftor Combination	Phase 3	Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	-	-
VX-121 (Suspension)	Phase 2	Cystic Fibrosis	-	-
VX-661	Phase 2	Cystic Fibrosis	-
Cethrin	Phase 2	Spinal Cord Injury	-	-
VX-150	Phase 2	Osteoarthritis	-	-
Ivacaftor 25 mg/75 mg	Phase 2	Cystic Fibrosis	-	-
VX-702	Phase 2	Rheumatoid Arthritis	-	-
Inaxaplin	Phase 2	Proteinuric Kidney Disease	-	-
VX-121	Phase 2	Cystic Fibrosis	-
VX-787	Phase 2	Influenza Virus	-	-
VX-222	Phase 2	Chronic Hepatitis C Virus	-	-
VX-993	Phase 2	Acute Pain	-	-
VX-950	Phase 2	Hepatitis C	-	-
VX-445	Phase 2	Cystic Fibrosis	-	-
VX-670	Phase 2	Myotonic Dystrophy Type 1 (DM1)	-	-
VX-152	Phase 2	Cystic Fibrosis	-	-
VX-765	Phase 2	Partial Epilepsy	-	-
VX-659	Phase 2	Cystic Fibrosis	-	-
VX-440	Phase 2	Cystic Fibrosis	-	-
VX-522 mRNA therapy	Phase 2	Cystic Fibrosis	-	-
VX-561	Phase 2	Cystic Fibrosis	-	-
VX-864	Phase 2	Alpha1-Antitrypsin Deficiency	-	-
VCH-759 (BCH-27759)	Phase 2	Hepatitis C, Chronic	-	-
VX-135	Phase 2	Chronic Hepatitis C	-	-
Daclatasvir	Phase 2	Chronic Hepatitis C	-	-
VX-264	Phase 2	Type 1 Diabetes	-	-
Merimepodib	Phase 2	Hepatitis C	-	-
VX-407	Phase 2	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	-	-
peginterferon alfa-2a	Phase 2	Hepatitis C	-	-
VX-548	Phase 2	Acute Pain	Fast Track	-

Cystic Fibrosis

25 drugs in this indication

Acute Pain

5 drugs in this indication

Hepatitis C

4 drugs in this indication

Proteinuric Kidney Disease

2 drugs in this indication

Type 1 Diabetes

2 drugs in this indication

Rheumatoid Arthritis

2 drugs in this indication

Beta-Thalassemia

1 drug in this indication

Spinal Cord Injury

1 drug in this indication

Pain

1 drug in this indication

Influenza Virus

1 drug in this indication

Primary Membranous Nephropathy

1 drug in this indication

Partial Epilepsy

1 drug in this indication

Osteoarthritis

1 drug in this indication

Chronic Hepatitis C Virus

1 drug in this indication

Myotonic Dystrophy Type 1 (DM1)

1 drug in this indication

Sickle Cell Disease

1 drug in this indication

Chronic Hepatitis C

1 drug in this indication

Diabetic Peripheral Neuropathic Pain

1 drug in this indication

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

1 drug in this indication

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Vertex Pharmaceuticals Incorporated

Market Overview

VRTX News

Catalyst Timeline

Pipeline & FDA Submissions

Competitive Positions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals